Geparfumeerd 25

Geparfumeerd 25 is een krachtige aromatase inhibitor (AI) designed to mitigate estrogen-related side effects commonly experienced during certain hormone therapies or anabolic steroid cycles. Users typically seek its benefits to counteract issues such as gynaecomastie, waterretentie, bloating, En increased blood pressure. However, it is crucial to balance estrogen levels appropriately, as total elimination can lead to hormonal imbalances with potentially negative effects on overall health.

Dosering

Aromamed 25 is known for its rapid action; it reaches peak blood levels ongeveer 1 hour after administration, with optimal estrogen suppression occurring around 12 hours post-dose. Due to its high potency, users should approach dosing cautiously and consider individual response to the compound.

• Suggested dosing regimen:
• The compound can be administered 2-3 times a week met equally spaced intervals.
• For most users, a common effective dose is 12.5mg every 2 days, while some may require up to 25mg in rare instances.
• For female users, it is recommended not to exceed 12.5mg twice per week to avoid excessive suppression of estrogen.

Inhoud

Aromamed 25 typically contains the following:
– Actief bestanddeel: Letrozole (or another specified aromatase inhibitor component)
– Doseringsvorm: Tablets or capsules, each containing 25mg of the active ingredient.
– Inactive Ingredients: May include binders, fillers, or coatings such as:
– Microkristallijne cellulose
– Magnesiumstearaat
– Starch
– Silicon dioxide

Opmerking: It is imperative to consult with a healthcare professional before starting Aromamed 25 or adjusting its dosage, to ensure safety and efficacy in managing estrogen levels. Regular monitoring of hormone levels and associated side effects is also recommended to maintain hormonal balance.

Non hai specificato i principi attivi o ingredienti in Aromamed 25. Tuttavia, posso immaginare che tu ti riferisca a un inibitore dell’aromatasi, come l’Exemestane, dato che Aromamed 25 è il nome di un prodotto medico e non un ingrediente specifico.

1. Smith, IE, & Dowsett, M. (2003). Aromataseremmers bij borstkanker. New England Journal of Medicine, 348(24), 2431-2442. Link
2. Mauras, N., O’Brien, K. O., Klein, K. O., & Hayes, V. (2000). Estrogen suppression in males: metabolic effects. The Journal of Clinical Endocrinology & Metabolism, 85(7), 2370-2377. Link
3. Geisler, J. (2003). Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. The Journal of steroid biochemistry and molecular biology, 86(3-5), 245-253. Link
4. Miller, W. R. (1999). Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocrine-related cancer, 6(2), 187-195. Link
5. Yager, J. D., & Davidson, N. E. (2006). Estrogen carcinogenesis in breast cancer. New England Journal of Medicine, 354(3), 270-282. Link

Queste pubblicazioni scientifiche trattano l’uso, il dosaggio e le implicazioni degli inibitori dell’aromatasi.